Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Azacitidine + Gilteritinib in R/R FLT3-mutated AML
NCT06022003Phase 2Recruiting
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Jan 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in acute myeloid leukemia (AML), sponsored by French Innovative Leukemia Organisation. Started Jan 2024; status: recruiting.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06022003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06022003.